Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society
Rhea-AI Summary
Korro Bio, Inc. (Nasdaq: KRRO), a biopharmaceutical company developing RNA-editing genetic medicines, announced presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal, October 6-9, 2024. The company will deliver one oral and two poster presentations.
The oral presentation, by Dr. Venkat Krishnamurthy, Senior VP and Head of Platform, will focus on KRRO-110, Korro's first development candidate for alpha-1 antitrypsin deficiency (AATD). This inherited disorder is caused by single nucleotide variants in the SERPINA1 gene.
The two poster presentations will cover:
- Purification of Human ADAR for evaluating oligo-directed RNA editing
- Using ADAR1 chimeric eCLIP to understand on-target and off-target behaviors of RNA editing oligonucleotides
Positive
- Korro Bio is presenting its research at a major industry conference, potentially increasing visibility and credibility
- The company has a development candidate (KRRO-110) for alpha-1 antitrypsin deficiency, indicating progress in its pipeline
- Korro is advancing its RNA editing technology, which could lead to new treatments for genetic disorders
Negative
- None.
News Market Reaction – KRRO
In the trading session that priced this news, KRRO declined 3.16%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced one oral and two poster presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal taking place on October 6-9, 2024.
Venkat Krishnamurthy, Ph.D., Senior Vice President, Head of Platform at Korro, will deliver an oral presentation on KRRO-110, the Company’s first development candidate for the potential treatment of alpha-1 antitrypsin deficiency (AATD), an inherited genetic disorder caused by single nucleotide variants (SNVs) in the SERPINA1 gene.
Oral Presentation Information:
Title: KRRO-110, an RNA Editing Oligonucleotide For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD)
Speaker: Venkat Krishnamurthy
Date: Monday, October 7
Time: 3:20 p.m. ET
Poster Presentation Information:
Title: Purification of Human ADAR Enables Evaluation of Oligo-Directed RNA Editing in a Cell-Free Environment that Predicts In Vivo Activity
Name: Agya Karki, Ph.D., Senior Scientist
Poster Number: P133
Title: Using ADAR1 chimeric eCLIP to understand the on-target and off-target behaviors of RNA editing oligonucleotides
Name: Zhiji Ren, Ph.D., Principal Scientist
Poster Number: P228
About Korro
Korro is a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to affect a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.
Korro Contact Information
Investors
IR@korrobio.com
Media
Glenn Silver
FINN Partners
Glenn.silver@finnpartners.com
